Difference between revisions of "Team:Austin UTexas/Sandbox Page"

Line 74: Line 74:
 
</div>
 
</div>
  
<br>
 
 
<br>
 
<br>
  
Line 104: Line 103:
 
<html>
 
<html>
  
 
<br>
 
 
<br>
 
<br>
  
 
<p style="font-family: verdana">Additionally, the BsmBI sites and overhangs in pYTK001 are flanking a <i>gfp</i> reporter gene. During the part assembly process, our DNA sequences of interest replaced this <i>gfp</i> reporter gene. This provided a phenotypic screen that allowed us to visually see which transformant colonies were negative and potentially positive. <b>Under UV illumination, positive colonies containing our intended part plasmid assembly did not exhibit fluorescence under the UV illumination, while negative colonies did (Fig. 2)</b>. The non-fluorescent colonies on the part plasmid transformation plates were miniprepped and subsequently sequence verified.</p>
 
<p style="font-family: verdana">Additionally, the BsmBI sites and overhangs in pYTK001 are flanking a <i>gfp</i> reporter gene. During the part assembly process, our DNA sequences of interest replaced this <i>gfp</i> reporter gene. This provided a phenotypic screen that allowed us to visually see which transformant colonies were negative and potentially positive. <b>Under UV illumination, positive colonies containing our intended part plasmid assembly did not exhibit fluorescence under the UV illumination, while negative colonies did (Fig. 2)</b>. The non-fluorescent colonies on the part plasmid transformation plates were miniprepped and subsequently sequence verified.</p>
  
<br>
 
 
<br>
 
<br>
  
Line 118: Line 114:
  
 
<br>
 
<br>
<br>
+
 
 
<a href="#top"><p>Back to Top</p></a>
 
<a href="#top"><p>Back to Top</p></a>
 
</div>
 
</div>
  
 
<div class="naviSection" id="section2">
 
<div class="naviSection" id="section2">
<br><br><br>
+
 
 +
<br>
 +
 
 
<h2 style="font-family: verdana; font-size: 30px">Testing constitutive <i>Lactococcal</i> promoters </h2>
 
<h2 style="font-family: verdana; font-size: 30px">Testing constitutive <i>Lactococcal</i> promoters </h2>
 
<p style="font-family: verdana"><b>After successfully creating the <i>gadB</i> gene and P8/P32 promoter part plasmids, the functionality of these part plasmids were then assessed by assembling them into cassette plasmids.</b></p>
 
<p style="font-family: verdana"><b>After successfully creating the <i>gadB</i> gene and P8/P32 promoter part plasmids, the functionality of these part plasmids were then assessed by assembling them into cassette plasmids.</b></p>
  
<br>
 
 
<br>
 
<br>
  
 
<p style="font-family: verdana">To test if our <i>Lactococcus lactis</i> constitutive promoters function well within <i>E. coli</i>, we created test cassette plasmids containing the <i>E2-Crimson</i> reporter gene (which encodes a red fluorescent protein) inserted downstream of either the P8 or P32 promoters using BsaI Golden Gate assembly. To create these test cassettes, we used the P8/P32 promoter part plasmids, the <i>E2-Crimson</i> part plasmid, an M13 terminator part plasmid, connector part plasmids, and the pYTK095 vector as the backbone <b>(Fig. 3).</b> <b>If the P8 and P32 promoters are functional in <i>E. coli</i>, we expected to observe red fluorescence in colonies transformed with our test cassette plasmids.</b></p>
 
<p style="font-family: verdana">To test if our <i>Lactococcus lactis</i> constitutive promoters function well within <i>E. coli</i>, we created test cassette plasmids containing the <i>E2-Crimson</i> reporter gene (which encodes a red fluorescent protein) inserted downstream of either the P8 or P32 promoters using BsaI Golden Gate assembly. To create these test cassettes, we used the P8/P32 promoter part plasmids, the <i>E2-Crimson</i> part plasmid, an M13 terminator part plasmid, connector part plasmids, and the pYTK095 vector as the backbone <b>(Fig. 3).</b> <b>If the P8 and P32 promoters are functional in <i>E. coli</i>, we expected to observe red fluorescence in colonies transformed with our test cassette plasmids.</b></p>
  
<br>
 
 
<br>
 
<br>
  
Line 139: Line 135:
 
<html>
 
<html>
  
<br>
 
 
<br>
 
<br>
  
Line 152: Line 147:
  
 
<br>
 
<br>
<br>
+
 
 
<a href="#top"><p>Back to Top</p></a>
 
<a href="#top"><p>Back to Top</p></a>
 
</div>
 
</div>
  
 
<div class="naviSection" id="section3">
 
<div class="naviSection" id="section3">
<br><br><br>
+
 
 +
<br>
 +
 
 
<h2 style="font-family: verdana; font-size: 30px">Testing for <i>gadB</i> overexpression in <i>E. coli</i></h2>
 
<h2 style="font-family: verdana; font-size: 30px">Testing for <i>gadB</i> overexpression in <i>E. coli</i></h2>
 
<p style="font-family: verdana"><b>Using Golden Gate Assembly, we created cassette plasmids to test if the <i>gadB</i> gene could be overexpressed in <i>E. coli</i> via the P8 and P32 promoters. </b> These cassette plasmids contained the <i>gadB</i> gene inserted downstream of either the P8 or P32 promoters. To make our <i>gadB</i> test cassette plasmids, we used pYTK095 as our backbone and part plasmids containing the P8/P32 promoters, <i>gadB</i> gene, M13 terminator, and connector sequences <b>(Fig. 5).</b></p>
 
<p style="font-family: verdana"><b>Using Golden Gate Assembly, we created cassette plasmids to test if the <i>gadB</i> gene could be overexpressed in <i>E. coli</i> via the P8 and P32 promoters. </b> These cassette plasmids contained the <i>gadB</i> gene inserted downstream of either the P8 or P32 promoters. To make our <i>gadB</i> test cassette plasmids, we used pYTK095 as our backbone and part plasmids containing the P8/P32 promoters, <i>gadB</i> gene, M13 terminator, and connector sequences <b>(Fig. 5).</b></p>
  
<br>
 
 
<br>
 
<br>
  
Line 172: Line 168:
 
<br>
 
<br>
  
<p>Similar to the pYTK001 entry vector in part assembly, the pYTK095 backbone used for cassette assembly contained a <i>gfp</i> reporter gene that is replaced by sequences of interest. This allowed us to easily perform a phenotypic screen for positive colonies. <b>Non-fluorescent colonies may potentially have had the correct cassette assembly, while fluorescent colonies did not (Fig. 6).</b></p>
+
<p style="font-family: verdana">Similar to the pYTK001 entry vector in part assembly, the pYTK095 backbone used for cassette assembly contained a <i>gfp</i> reporter gene that is replaced by sequences of interest. This allowed us to easily perform a phenotypic screen for positive colonies. <b>Non-fluorescent colonies may potentially have had the correct cassette assembly, while fluorescent colonies did not (Fig. 6).</b></p>
  
  
Line 181: Line 177:
  
  
<p>The non-fluorescent colonies were then screened using colony PCR, and positive colonies were then miniprepped and sequenced. <b>The sequencing results indicated that there were several mutations within the <i>gadB</i> gene in the samples.</b> These mutations are recorded in <b>Table 1.</b></p>
+
<p style="font-family: verdana">The non-fluorescent colonies were then screened using colony PCR, and positive colonies were then miniprepped and sequenced. <b>The sequencing results indicated that there were several mutations within the <i>gadB</i> gene in the samples.</b> These mutations are recorded in <b>Table 1.</b></p>
  
  
Line 188: Line 184:
 
<html>
 
<html>
  
<br>
 
 
<br>
 
<br>
  
Line 194: Line 189:
 
<p style="font-family: verdana">Along with being one of the canonical amino acids utilized in protein synthesis, glutamate plays an important role as the main amino-group donor in the biosynthesis of nitrogen-containing compounds such as amino acids and nucleotides (4, 5). Thus, we hypothesized that <i>gadB</i> overexpression via the P8 and P32 constitutive promoters and the high-copy number ColE1 origin induced a high metabolic load on the cells by shunting away glutamate from essential anabolic pathways. We believed that transformants containing the mutationally degraded <i>gadB</i> gene were selected for. In contrast, transformants containing the functional <i>gadB</i> gene were selected against due to having a depletion of glutamate substrates needed for important cellular processes. </p>
 
<p style="font-family: verdana">Along with being one of the canonical amino acids utilized in protein synthesis, glutamate plays an important role as the main amino-group donor in the biosynthesis of nitrogen-containing compounds such as amino acids and nucleotides (4, 5). Thus, we hypothesized that <i>gadB</i> overexpression via the P8 and P32 constitutive promoters and the high-copy number ColE1 origin induced a high metabolic load on the cells by shunting away glutamate from essential anabolic pathways. We believed that transformants containing the mutationally degraded <i>gadB</i> gene were selected for. In contrast, transformants containing the functional <i>gadB</i> gene were selected against due to having a depletion of glutamate substrates needed for important cellular processes. </p>
  
<br>
 
 
<br>
 
<br>
  
<p><b>To troubleshoot this problem, we decided to use a backbone containing the low-copy number p15A origin for the cassette assembly (Fig. 7).</b></p>
+
<p style="font-family: verdana"><b>To troubleshoot this problem, we decided to use a backbone containing the low-copy number p15A origin for the cassette assembly (Fig. 7).</b></p>
  
  
Line 205: Line 199:
  
  
<p>Copy number reduction of our <i>gadB</i> overexpression cassette plasmids (accomplished by replacing the ColE1 origin with the p15A origin) was expected to decrease the overall amount of <i>gadB</i> expression, thereby decreasing the metabolic load imposed on the cells and the mutation rates observed in the <i>gadB</i> gene. <b>However, we also observed several mutations within the <i>gadB</i> gene in the potentially positive cassette plasmids sequenced.</b> The observed mutations are detailed in Table 2.</p>
+
<p style="font-family: verdana">Copy number reduction of our <i>gadB</i> overexpression cassette plasmids (accomplished by replacing the ColE1 origin with the p15A origin) was expected to decrease the overall amount of <i>gadB</i> expression, thereby decreasing the metabolic load imposed on the cells and the mutation rates observed in the <i>gadB</i> gene. <b>However, we also observed several mutations within the <i>gadB</i> gene in the potentially positive cassette plasmids sequenced.</b> The observed mutations are detailed in Table 2.</p>
  
 
</html>
 
</html>
Line 211: Line 205:
 
<html>
 
<html>
  
<br>
 
 
<br>
 
<br>
  
<p><b>With our theory that <i>gadB</i>overexpression was toxic to bacterial cells, we attempted to inducibly express the <i>gadB</i> gene using the regulatory elements of the lac operon to see if controlled <i>gadB</i> expression was even possible in <i>E. coli</i></b>. Our IPTG-inducible <i>gadB</i> expression cassette plasmid was assembled using a lac promoter and operator part plasmid, the <i>gadB</i> gene part plasmid, the M13 terminator part plasmid, connector part plasmids, a CP25 promoter part plasmid, a lacI part plasmid, and the SpecR and p15A origin part plasmid <b>(Fig. 8)</b>. Under this assembled regulatory system, in the absence of IPTG (an analog of the allolactose inducer) the LacI repressor will bind to the lac operator region to block transcription of the <i>gadB</i> gene. When present, IPTG will act as an inducer and bind to the LacI repressor to decrease its binding affinity for the lac operator, thereby allowing for <i>gadB</i> expression. This IPTG-inducible system provides us with a mechanism of controlling <i>gadB</i> expression. <b>Positive colonies have been identified and sequence verification is currently underway.</b> </p>
+
<p style="font-family: verdana"><b>With our theory that <i>gadB</i>overexpression was toxic to bacterial cells, we attempted to inducibly express the <i>gadB</i> gene using the regulatory elements of the lac operon to see if controlled <i>gadB</i> expression was even possible in <i>E. coli</i></b>. Our IPTG-inducible <i>gadB</i> expression cassette plasmid was assembled using a lac promoter and operator part plasmid, the <i>gadB</i> gene part plasmid, the M13 terminator part plasmid, connector part plasmids, a CP25 promoter part plasmid, a lacI part plasmid, and the SpecR and p15A origin part plasmid <b>(Fig. 8)</b>. Under this assembled regulatory system, in the absence of IPTG (an analog of the allolactose inducer) the LacI repressor will bind to the lac operator region to block transcription of the <i>gadB</i> gene. When present, IPTG will act as an inducer and bind to the LacI repressor to decrease its binding affinity for the lac operator, thereby allowing for <i>gadB</i> expression. This IPTG-inducible system provides us with a mechanism of controlling <i>gadB</i> expression. <b>Positive colonies have been identified and sequence verification is currently underway.</b> </p>
  
  
Line 224: Line 217:
  
 
<br>
 
<br>
<br>
+
 
 
<a href="#top"><p>Back to Top</p></a>
 
<a href="#top"><p>Back to Top</p></a>
 
</div>
 
</div>
Line 230: Line 223:
 
<h2 style="font-family: verdana; font-size: 28px">Creating a Golden Gate compatible shuttle vector</h2>
 
<h2 style="font-family: verdana; font-size: 28px">Creating a Golden Gate compatible shuttle vector</h2>
  
<p><b>We wanted to assemble our final GABA overexpression cassette plasmid using the shuttle vector pMSP3535 as the backbone <b>(Fig. 9).</b> To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in <i>E. coli</i> and a pAMb1 origin for replication in Gram-positive bacteria including <i>Lactobacillus</i> species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which <i>Lactobacillus plantarum</i> is naturally susceptible to (7).</p>
+
<p style="font-family: verdana"><b>We wanted to assemble our final GABA overexpression cassette plasmid using the shuttle vector pMSP3535 as the backbone <b>(Fig. 9).</b> To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in <i>E. coli</i> and a pAMb1 origin for replication in Gram-positive bacteria including <i>Lactobacillus</i> species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which <i>Lactobacillus plantarum</i> is naturally susceptible to (7).</p>
  
<br>
 
 
<br>
 
<br>
  
Line 239: Line 231:
 
<html>
 
<html>
  
<br>
 
 
<br>
 
<br>
  
<p>The process of making the pMSP3535 vector Golden Gate compatible involved two steps: 1) assembling the pMSP3535 backbone (pAMb1 origin and erythromycin resistance gene) with a new ColE1 origin; 2) assembling a gfp dropout part to the assembly of the pMSP3535 backbone and the new ColE1 origin <b>(Fig. 10).</b></p>
+
<p style="font-family: verdana">The process of making the pMSP3535 vector Golden Gate compatible involved two steps: 1) assembling the pMSP3535 backbone (pAMb1 origin and erythromycin resistance gene) with a new ColE1 origin; 2) assembling a gfp dropout part to the assembly of the pMSP3535 backbone and the new ColE1 origin <b>(Fig. 10).</b></p>
  
<br>
 
 
<br>
 
<br>
  
Line 251: Line 241:
 
<html>
 
<html>
  
<br>
 
 
<br>
 
<br>
  
<p<b>Since the original pMSP3535 vector contained two illegal BsaI sites within the ColE1 origin, we sought to replace this ColE1 origin with a BsaI-free one isolated from pYTK001.</b> This assembly process involved linearizing and adding BsmBI sites and compatible overhangs to the pMSP3535 backbone and the pYTK001 ColE1 origin via PCR. After the pMSP3535 backbone and ColE1 origin were successfully amplified by PCR <b>(Fig. 11a)</b>, they were joined together using BsmBI assembly. Diagnostic PCR was performed on pMSP3535 + ColE1 minipreps from <i>E. coli</i> transformants to screen for positive samples containing both the pMSP3535 backbone and the ColE1 inserts (Fig. 11b). <b>After confirming the presence of the pMSP3535 vector and ColE1 origin, we partially sequence-confirmed the two miniprep samples.</b></p>
+
<p style="font-family: verdana><b>Since the original pMSP3535 vector contained two illegal BsaI sites within the ColE1 origin, we sought to replace this ColE1 origin with a BsaI-free one isolated from pYTK001.</b> This assembly process involved linearizing and adding BsmBI sites and compatible overhangs to the pMSP3535 backbone and the pYTK001 ColE1 origin via PCR. After the pMSP3535 backbone and ColE1 origin were successfully amplified by PCR <b>(Fig. 11a)</b>, they were joined together using BsmBI assembly. Diagnostic PCR was performed on pMSP3535 + ColE1 minipreps from <i>E. coli</i> transformants to screen for positive samples containing both the pMSP3535 backbone and the ColE1 inserts (Fig. 11b). <b>After confirming the presence of the pMSP3535 vector and ColE1 origin, we partially sequence-confirmed the two miniprep samples.</b></p>
  
<br>
 
 
<br>
 
<br>
  
Line 262: Line 250:
 
[[File:T--Austin_UTexas--pMSP3535Gel.jpg|thumb|center|700px|Figure 11. (A) Agarose gel of successful PCR for the pMSP3535 backbone and the ColE1 origin. Lane 1 contains a negative PCR control. Lanes 2 and 3 contain the ColE1 origin (around 800 bp) and pMSP3535 backbone PCR products (around 4.3 kb). (B) Agarose gel of diagnostic PCR of miniprep samples from pMSP3535 + ColE1 transformants. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control for the pMSP3535 backbone, while lanes 3 and 4 contain the pMSP3535 PCR from two miniprep samples. Lane 7 contains a positive PCR control for the ColE1 origin, while lanes 8 and 9 contain the ColE1 PCR from the same two miniprep samples. Evidently, the pMSP3535 backbone and ColE1 origin is present in both tested miniprep samples.]]
 
[[File:T--Austin_UTexas--pMSP3535Gel.jpg|thumb|center|700px|Figure 11. (A) Agarose gel of successful PCR for the pMSP3535 backbone and the ColE1 origin. Lane 1 contains a negative PCR control. Lanes 2 and 3 contain the ColE1 origin (around 800 bp) and pMSP3535 backbone PCR products (around 4.3 kb). (B) Agarose gel of diagnostic PCR of miniprep samples from pMSP3535 + ColE1 transformants. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control for the pMSP3535 backbone, while lanes 3 and 4 contain the pMSP3535 PCR from two miniprep samples. Lane 7 contains a positive PCR control for the ColE1 origin, while lanes 8 and 9 contain the ColE1 PCR from the same two miniprep samples. Evidently, the pMSP3535 backbone and ColE1 origin is present in both tested miniprep samples.]]
 
<html>
 
<html>
 
  
<br>
 
 
<br>
 
<br>
  
<p <b>To this pMSP3535 + ColE1 assembly, we wanted to add a <i>gfp</i> dropout part containing internal BsaI sites that will generate overhangs compatible with those in the P8/P32 promoter and M13 terminator part plasmids.</b> Additionally, the incorporation of this <i>gfp</i> dropout part will also allow us to visually screen for positive and negative transformants based on their fluorescence. BsmBI sites and compatible overhangs were added to the <i>gfp</i> dropout part by PCR amplifying it from pYTK047. We have been attempting to linearize and add BsmBI sites and overhangs to the positive pMSP3535 + ColE1 assemblies via PCR, with no success. However, results from diagnostic digests suggested that our assemblies may have contained extra, undesired DNA such as IS elements (Fig. 12). <b>Thus, as of right now, we are screening for more positive pMSP3535 + ColE1 transformants.</b> Once we have trouble-shooted this problem, the pMSP3535 + ColE1 and the <i>gfp</i> dropout PCR products will be joined through BsmBI assembly to form the final Golden Gate compatible pMSP3535 vector.  
+
<p style="font-family: verdana><b>To this pMSP3535 + ColE1 assembly, we wanted to add a <i>gfp</i> dropout part containing internal BsaI sites that will generate overhangs compatible with those in the P8/P32 promoter and M13 terminator part plasmids.</b> Additionally, the incorporation of this <i>gfp</i> dropout part will also allow us to visually screen for positive and negative transformants based on their fluorescence. BsmBI sites and compatible overhangs were added to the <i>gfp</i> dropout part by PCR amplifying it from pYTK047. We have been attempting to linearize and add BsmBI sites and overhangs to the positive pMSP3535 + ColE1 assemblies via PCR, with no success. However, results from diagnostic digests suggested that our assemblies may have contained extra, undesired DNA such as IS elements (Fig. 12). <b>Thus, as of right now, we are screening for more positive pMSP3535 + ColE1 transformants.</b> Once we have trouble-shooted this problem, the pMSP3535 + ColE1 and the <i>gfp</i> dropout PCR products will be joined through BsmBI assembly to form the final Golden Gate compatible pMSP3535 vector.  
  
 
<br>
 
<br>
<br>
 
 
  
 
</html>
 
</html>
Line 277: Line 261:
 
<html>
 
<html>
  
 
<br>
 
 
<br>
 
<br>
 
  
 
<h2 style="font-family: verdana; font-size: 28px">Assessing erythromycin susceptibility of <i>E. coli</i></h2>
 
<h2 style="font-family: verdana; font-size: 28px">Assessing erythromycin susceptibility of <i>E. coli</i></h2>
 +
 
<br>
 
<br>
<br>
+
 
 
<p Since we are creating our Golden Gate compatible pMSP3535 shuttle vector in <i>E. coli</i>, we wanted to determine the natural susceptibility of <i>E. coli</i> to erythromycin as the minimum concentration to use has not been established clearly in the literature. Thus, we performed an erythromycin minimum inhibitory concentration test in liquid LB media <b>(Fig. 13).</b> After one-day incubation, we observed that <i>E. coli</i> was resistant up to around 150 µg/mL of erythromycin. <b>From this experiment, we have determined that the optimal erythromycin concentration for selecting against <i>E. coli</i> in liquid culture is around 200-250 µg/mL.</b></p>
 
<p Since we are creating our Golden Gate compatible pMSP3535 shuttle vector in <i>E. coli</i>, we wanted to determine the natural susceptibility of <i>E. coli</i> to erythromycin as the minimum concentration to use has not been established clearly in the literature. Thus, we performed an erythromycin minimum inhibitory concentration test in liquid LB media <b>(Fig. 13).</b> After one-day incubation, we observed that <i>E. coli</i> was resistant up to around 150 µg/mL of erythromycin. <b>From this experiment, we have determined that the optimal erythromycin concentration for selecting against <i>E. coli</i> in liquid culture is around 200-250 µg/mL.</b></p>
  
<br>
 
 
<br>
 
<br>
  
Line 293: Line 274:
 
[[File:T--Austin_UTexas--erymic.jpg|thumb|center|800px|<b>Figure 13.</b> Erythromycin minimum inhibitory concentration tests for <i>E. coli</i> in liquid media. From left to right: 0 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 200 µg/mL, 250 µg/mL, 300 µg/mL, 350 µg/mL, and 400 µg/mL.]]
 
[[File:T--Austin_UTexas--erymic.jpg|thumb|center|800px|<b>Figure 13.</b> Erythromycin minimum inhibitory concentration tests for <i>E. coli</i> in liquid media. From left to right: 0 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 200 µg/mL, 250 µg/mL, 300 µg/mL, 350 µg/mL, and 400 µg/mL.]]
 
<html>
 
<html>
 
  
 
<br>
 
<br>
 
  
 
<div class="naviSection" id="section4">
 
<div class="naviSection" id="section4">
<br><br><br>
+
<br>
 
<div style="background-color: lightcyan;padding:14px;">
 
<div style="background-color: lightcyan;padding:14px;">
 
<h2 style="font-family: verdana; font-size: 30px"><i>Lactobacillus plantarum</i> transformation</h2>
 
<h2 style="font-family: verdana; font-size: 30px"><i>Lactobacillus plantarum</i> transformation</h2>
  
 +
<br>
  
 
<p style="font-family: verdana"><i> Lactobacillus plantarum </i> is a gram-positive lactic acid producing bacteria, so it requires a different growth media than we typically use in our lab. In 1954, Briggs agar was developed (8). This media was designed for lactobacilli, but was not sufficient for many species, including <i> Lactobacillus plantarum </i>, so a different non-selective media for general lactobacilli was developed in 1960 by Man, Rogosa and Sharpe and named MRS (9). We have exclusively grown our <i> Lactobacillus plantarum </i> on MRS media. Further, we grew <i> Lactobacillus plantarum </i> in a CO2 incubator as referenced in most literature we studied (10-12). The metabolic pathways in the bacteria alters when grown aerobically to produce excess acetate (13) and less lactic acid. Because we intend to utilize this bacteria in a fermentable food, a change in this metabolic pathway would not benefit our ultimate goal.</p>
 
<p style="font-family: verdana"><i> Lactobacillus plantarum </i> is a gram-positive lactic acid producing bacteria, so it requires a different growth media than we typically use in our lab. In 1954, Briggs agar was developed (8). This media was designed for lactobacilli, but was not sufficient for many species, including <i> Lactobacillus plantarum </i>, so a different non-selective media for general lactobacilli was developed in 1960 by Man, Rogosa and Sharpe and named MRS (9). We have exclusively grown our <i> Lactobacillus plantarum </i> on MRS media. Further, we grew <i> Lactobacillus plantarum </i> in a CO2 incubator as referenced in most literature we studied (10-12). The metabolic pathways in the bacteria alters when grown aerobically to produce excess acetate (13) and less lactic acid. Because we intend to utilize this bacteria in a fermentable food, a change in this metabolic pathway would not benefit our ultimate goal.</p>
Line 308: Line 288:
 
<button class="accordion">MRS Media</button>
 
<button class="accordion">MRS Media</button>
 
<div class="panel">
 
<div class="panel">
   <ul>
+
   <ul style="font-family: verdana">
 
   <li>MRS broth was prepared using 55g of Difco MRS broth powder in 1L of distilled water. The solution was then autoclaved and stored in a 4 degree refrigerator along with the Difco MRS powder.</li>
 
   <li>MRS broth was prepared using 55g of Difco MRS broth powder in 1L of distilled water. The solution was then autoclaved and stored in a 4 degree refrigerator along with the Difco MRS powder.</li>
 
   <li>MRS agar was prepared by mixing 55g of Difco MRS broth powder and 15g of agar flakes in 1 L of water. The solution was then autoclaved and stored in a 4 degree refrigerator along with the Difco MRS powder.</li>
 
   <li>MRS agar was prepared by mixing 55g of Difco MRS broth powder and 15g of agar flakes in 1 L of water. The solution was then autoclaved and stored in a 4 degree refrigerator along with the Difco MRS powder.</li>
Line 321: Line 301:
 
<div class="panel">
 
<div class="panel">
 
   <br>
 
   <br>
   <h4>Materials Needed</h4>
+
   <h4 style="font-family: verdana">Materials Needed</h4>
 
   <ul>
 
   <ul>
 
   <li>MRS liquid media</li>
 
   <li>MRS liquid media</li>
Line 336: Line 316:
 
   </br>
 
   </br>
 
   <h4>Preparation of Recipient Cell Stocks</h4>
 
   <h4>Preparation of Recipient Cell Stocks</h4>
   <ol>
+
   <ol style="font-family: verdana">
 
   <li>Inoculate 10-25 mL of -80 &#2103 L. Plantarum stocks in MRS broth at 37 &#2103 CO2 incubator, overnight without shaking.</li>
 
   <li>Inoculate 10-25 mL of -80 &#2103 L. Plantarum stocks in MRS broth at 37 &#2103 CO2 incubator, overnight without shaking.</li>
 
   <li>Subculture by incubating culture in a 200 mL of prewarmed MRS broth. Add culture until OD600 is 0.1.</li>
 
   <li>Subculture by incubating culture in a 200 mL of prewarmed MRS broth. Add culture until OD600 is 0.1.</li>
Line 350: Line 330:
 
   </ol>
 
   </ol>
 
   <h4>Treatment of Cells Prior to Electroporation</h4>
 
   <h4>Treatment of Cells Prior to Electroporation</h4>
   <ol>
+
   <ol style="font-family: verdana">
 
   <li>Thaw on Ice.</li>
 
   <li>Thaw on Ice.</li>
 
   <li>Suspend cells in  900μL of cold, sterile, distilled water for 30 min.</li>
 
   <li>Suspend cells in  900μL of cold, sterile, distilled water for 30 min.</li>
Line 356: Line 336:
 
   <li>After pretreatment, the cells were pelleted for 2-3 minutes in a microcentrifuge, washed once in 1 mL of cold, sterile, 30% PEG solution and suspended in 0.5-0.6 mL cold, sterile PEG solution for electroporation.</li>
 
   <li>After pretreatment, the cells were pelleted for 2-3 minutes in a microcentrifuge, washed once in 1 mL of cold, sterile, 30% PEG solution and suspended in 0.5-0.6 mL cold, sterile PEG solution for electroporation.</li>
 
   </ol>
 
   </ol>
   <h4>Electroporation</h4>
+
   <h4 style="font-family: verdana">Electroporation</h4>
   <ol>
+
   <ol style="font-family: verdana">
 
   <li>Isolate intended vector (Lactobacillus plantarum experiment as of 09/06/17 has been using pMSP3535).</li>
 
   <li>Isolate intended vector (Lactobacillus plantarum experiment as of 09/06/17 has been using pMSP3535).</li>
 
   <li>200 ng/transformation of plasmid DNA is mixed with 100μL of cell suspension and transferred to a prechilled electroporation cuvette with a 0.2 cm gap.</li>
 
   <li>200 ng/transformation of plasmid DNA is mixed with 100μL of cell suspension and transferred to a prechilled electroporation cuvette with a 0.2 cm gap.</li>

Revision as of 06:28, 1 November 2017


Click on one of the images below to learn more about our results!


Although bacteria can naturally synthesize GABA, we wanted to increase expression of the gadB gene and subsequently GABA production in order to imbue our probiotic with a more potent medicinal quality, with the idea that this GABA-overproducing probiotic can then be consumed by patients with bowel disorders or anxiety (1). Overexpression of the gadB gene will be accomplished by placing it under the control of either the P8 or P32 constitutive promoters from Lactococcus lactis (2).

To make our GABA-producing probiotic we first needed to assemble a GABA overexpression cassette plasmid using the Golden Gate assembly method. The intention here is that bacteria containing this GABA overexpression cassette plasmid should produce high levels of GABA. In short, Golden Gate Assembly is a new cloning method that allows for the creation of a multi-part DNA assembly (i.e. cassette plasmid) in a single reaction through the use of DNA parts containing specific, predefined suffixes and prefixes with recognition sites for Type IIs restriction enzymes (e.g. BsmBI and BsaI). The specificity of these suffixes and prefixes provides directionality of the desired DNA parts during the assembly process. For our purposes, we used the MoClo Yeast Tool Kit developed by John Dueber (3).


Creating a Golden Gate compatible shuttle vector

We wanted to assemble our final GABA overexpression cassette plasmid using the shuttle vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in E. coli and a pAMb1 origin for replication in Gram-positive bacteria including Lactobacillus species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which Lactobacillus plantarum is naturally susceptible to (7).


Figure 9. Golden Gate assembly of the GABA final overexpression cassette plasmid with the Golden Gate compatible pMSP3535 vector and the P8/P32 promoter, gadB gene, and M13 terminator part plasmids.


The process of making the pMSP3535 vector Golden Gate compatible involved two steps: 1) assembling the pMSP3535 backbone (pAMb1 origin and erythromycin resistance gene) with a new ColE1 origin; 2) assembling a gfp dropout part to the assembly of the pMSP3535 backbone and the new ColE1 origin (Fig. 10).


Figure 10. Assembly workflow for creating the Golden Gate compatible pMSP3535 backbone. The first step involves replacing the ColE1 origin in the pMSP3535 backbone with a new ColE1 origin from pYTK001 to create a pMSP3535 + ColE1 assembly. The second step involves combining the pMSP3535 + ColE1 assembly with a gfp dropout to form the final Golden Gate compatible vector to be used to create our GABA overexpression plasmid.


Figure 11. (A) Agarose gel of successful PCR for the pMSP3535 backbone and the ColE1 origin. Lane 1 contains a negative PCR control. Lanes 2 and 3 contain the ColE1 origin (around 800 bp) and pMSP3535 backbone PCR products (around 4.3 kb). (B) Agarose gel of diagnostic PCR of miniprep samples from pMSP3535 + ColE1 transformants. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control for the pMSP3535 backbone, while lanes 3 and 4 contain the pMSP3535 PCR from two miniprep samples. Lane 7 contains a positive PCR control for the ColE1 origin, while lanes 8 and 9 contain the ColE1 PCR from the same two miniprep samples. Evidently, the pMSP3535 backbone and ColE1 origin is present in both tested miniprep samples.


Figure 12. Agarose gel of pMSP3535 + ColE1 assembly diagnostic digests. Lane 1 contains the undigested plasmid assembly. Lane 2 contains the ClaI-digested plasmid with expected 400 bp and 4.6 kb bands. The actual band generated is apparently above 10 kb. Lane 3 contains the XmnI-digested plasmid with expected 200 bp, 1.5 kb, and 3.3 kb bands. The generated band sizes were 2.5 kb and 4 kb. Lane 4 contains the KpnI-digested assembly with an expected 5.1 kb band. The generated band size was 6 kb. Lane 5 contains the Bg1II-digested assembly with an expected 5.1 kb band. The generated band size was 8 kb.


Assessing erythromycin susceptibility of E. coli


E. coli, we wanted to determine the natural susceptibility of E. coli to erythromycin as the minimum concentration to use has not been established clearly in the literature. Thus, we performed an erythromycin minimum inhibitory concentration test in liquid LB media (Fig. 13). After one-day incubation, we observed that E. coli was resistant up to around 150 µg/mL of erythromycin. From this experiment, we have determined that the optimal erythromycin concentration for selecting against E. coli in liquid culture is around 200-250 µg/mL.


Figure 13. Erythromycin minimum inhibitory concentration tests for E. coli in liquid media. From left to right: 0 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 200 µg/mL, 250 µg/mL, 300 µg/mL, 350 µg/mL, and 400 µg/mL.